The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
复制标题
DOI：
10.1111/imr.12521
复制
发表时间：
2017-03
影响因子：
8.7
通讯作者：
Zang X
中科院分区：
文献类型：
--
作者：
Janakiram M;Shah UA;Liu W;Zhao A;Schoenberg MP;Zang X
B7-CD 28配体和受体家族在T细胞共刺激和共抑制中发挥重要作用。从系统发育学上，它们可以分为三组。最近发现的III组新分子[B7-H3（CD 276）、B7 x（B7-H4/B7 S1）和HHLA 2（B7 H7/B7-H5）/TMIGD 2（IGPR-1/CD 28 H）]扩大了治疗人类疾病的治疗可能性。本文就B7-H3、B7 x、HHLA 2和TMIGD 2的发现、结构和功能进行综述。我们还讨论了它们在重要的病理状态，如癌症，自身免疫性疾病，移植和感染中的作用。各种免疫治疗方法正在出现，包括拮抗性单克隆抗体和激动性融合蛋白，以抑制或增强癌症和自身免疫性疾病中的这些分子和途径。
The B7-CD28 family of ligands and receptors play important roles in T cell costimulation and coinhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules [B7-H3 (CD276), B7x (B7-H4/B7S1) and HHLA2 (B7H7/B7-H5)/TMIGD2 (IGPR-1/CD28H)] of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure and function of B7-H3, B7x, HHLA2 and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.